CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
CPRX on Nasdaq
Shares outstanding
123,180,519
Price per share
$24.58
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
103,868,246
Total reported value
$2,422,426,107
% of total 13F portfolios
0%
Share change
-255,188
Value change
+$5,254,019
Number of holders
369
Price from insider filings
$24.58
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 14% $399,180,432 16,892,951 BlackRock, Inc. 31 Mar 2025
STATE STREET CORP 5.2% $126,186,124 6,405,387 STATE STREET CORPORATION 30 Sep 2025
Flynn James E 2.6% $74,033,050 3,133,011 Deerfield Mgmt, L.P. 31 Dec 2024

As of 31 Dec 2025, 369 institutional investors reported holding 103,868,246 shares of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX). This represents 84% of the company’s total 123,180,519 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) together control 61% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 15% 18,626,781 +2.3% 0.01% $434,749,068
VANGUARD GROUP INC 6.8% 8,432,247 -3.2% 0% $196,808,646
STATE STREET CORP 5.6% 6,907,622 +7.8% 0.01% $161,223,897
DEERFIELD MANAGEMENT COMPANY, L.P. 4% 4,911,161 -1.3% 1.5% $114,626,498
Fundsmith LLP 2.7% 3,363,807 0% 0.46% $78,511,255
AMERICAN CENTURY COMPANIES INC 2.5% 3,025,271 +20% 0.04% $70,609,825
DIMENSIONAL FUND ADVISORS LP 2.4% 2,996,297 +22% 0.01% $69,932,608
MORGAN STANLEY 2.4% 2,933,399 +59% 0% $68,465,565
GEODE CAPITAL MANAGEMENT, LLC 2.4% 2,900,337 +0.35% 0% $67,704,365
RENAISSANCE TECHNOLOGIES LLC 2.2% 2,650,077 -25% 0.1% $61,852,797
BANK OF AMERICA CORP /DE/ 1.8% 2,199,842 -4% 0% $51,344,312
ROYCE & ASSOCIATES LP 1.6% 1,910,767 -6.1% 0.45% $44,597,302
JANUS HENDERSON GROUP PLC 1.4% 1,719,767 +201% 0.02% $40,123,723
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.3% 1,617,208 +24% 0.02% $37,745,635
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1.1% 1,356,499 +1.8% 0% $31,660,687
Invesco Ltd. 1.1% 1,293,478 +4.9% 0% $30,189,776
Boston Partners 1% 1,231,372 -4.6% 0.03% $28,539,969
NORTHERN TRUST CORP 0.98% 1,211,973 -4.1% 0% $28,287,449
KENNEDY CAPITAL MANAGEMENT LLC 0.98% 1,209,692 +14% 0.6% $28,234,211
MILLENNIUM MANAGEMENT LLC 0.81% 993,647 -16% 0.02% $23,191,721
GOLDMAN SACHS GROUP INC 0.8% 979,543 -2.7% 0% $22,862,534
VICTORY CAPITAL MANAGEMENT INC 0.72% 884,605 +112% 0.01% $20,646,681
RAYMOND JAMES FINANCIAL INC 0.68% 841,914 +8.9% 0.01% $19,624,682
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 0.63% 778,591 0% 0.03% $18,172,000
Legal & General Group Plc 0.63% 776,172 +0.27% 0% $18,115,855

Institutional Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 103,868,246 $2,422,426,107 +$5,254,019 $23.34 369
2025 Q3 103,323,297 $2,035,619,506 +$33,916,547 $19.70 357
2025 Q2 101,339,025 $2,199,165,165 +$74,610,948 $21.70 360
2025 Q1 97,995,812 $2,374,736,976 +$45,703,179 $24.25 365
2024 Q4 97,462,582 $2,034,900,504 +$38,258,566 $20.87 333
2024 Q3 95,380,838 $1,896,646,482 -$35,292,712 $19.88 312
2024 Q2 96,983,113 $1,502,403,827 +$11,987,767 $15.49 269
2024 Q1 96,270,213 $1,534,339,181 +$191,142,132 $15.94 268
2023 Q4 84,453,649 $1,419,515,333 +$62,962,605 $16.81 259
2023 Q3 81,157,485 $948,788,519 -$23,397,502 $11.69 254
2023 Q2 82,218,793 $1,104,943,728 -$95,298,712 $13.44 243
2023 Q1 88,787,264 $1,472,124,820 +$71,196,268 $16.58 256
2022 Q4 84,107,036 $1,564,456,429 -$12,268,287 $18.60 252
2022 Q3 85,176,091 $1,093,105,879 +$187,635,691 $12.83 220
2022 Q2 75,651,199 $530,307,280 +$37,811,777 $7.01 175
2022 Q1 70,838,632 $586,598,135 +$41,265,648 $8.29 181
2021 Q4 66,018,446 $446,683,816 +$3,690,649 $6.77 160
2021 Q3 65,162,167 $345,106,769 -$2,224,745 $5.30 138
2021 Q2 65,482,202 $376,526,274 -$10,746,528 $5.75 137
2021 Q1 67,671,701 $311,885,548 +$10,809,324 $4.61 130
2020 Q4 66,576,359 $222,408,153 -$12,651,094 $3.34 131
2020 Q3 67,907,092 $201,992,589 +$603,491 $2.97 140
2020 Q2 64,719,712 $299,102,386 -$2,974,113 $4.62 138
2020 Q1 65,840,014 $253,546,747 +$11,634,204 $3.85 128
2019 Q4 62,834,633 $235,638,867 -$30,765,313 $3.75 127
2019 Q3 61,617,508 $327,170,529 +$8,126,558 $5.31 117
2019 Q2 61,553,639 $236,256,732 -$4,762,099 $3.84 99
2019 Q1 61,491,932 $313,611,586 +$64,665,968 $5.10 87
2018 Q4 49,136,126 $94,337,873 -$22,145,979 $1.92 85
2018 Q3 51,043,397 $192,937,538 -$11,273,654 $3.78 96
2018 Q2 54,196,334 $169,201,579 +$2,782,969 $3.12 98
2018 Q1 54,723,682 $130,787,787 -$11,120,389 $2.39 97
2017 Q4 56,055,280 $219,183,091 +$80,363,139 $3.91 105
2017 Q3 35,604,156 $89,681,592 +$4,372,606 $2.52 77
2017 Q2 33,946,250 $93,689,694 +$24,746,037 $2.76 68
2017 Q1 25,299,931 $49,329,000 +$4,788,629 $1.95 51
2016 Q4 23,812,013 $25,000,000 +$512,936 $1.05 51
2016 Q3 23,293,467 $25,386,000 -$1,705,125 $1.09 46
2016 Q2 25,351,615 $17,997,000 -$12,327,656 $0.71 57
2016 Q1 36,952,362 $43,231,000 -$15,825,279 $1.17 73
2015 Q4 42,424,296 $103,944,627 -$6,424,568 $2.45 86
2015 Q3 44,724,461 $134,180,687 +$3,442,159 $3.00 88
2015 Q2 43,473,000 $179,861,198 +$18,861,290 $4.13 86
2015 Q1 38,864,127 $168,166,940 +$54,418,957 $4.33 64
2014 Q4 27,360,884 $81,277,000 +$8,330,747 $2.97 49
2014 Q3 23,623,262 $78,388,100 +$8,077,982 $3.32 51
2014 Q2 22,284,591 $56,380,420 +$29,950,485 $2.53 46
2014 Q1 10,454,712 $23,627,120 +$2,788,485 $2.26 36